February 24, 2026

Adjuvant Coformulated Vibostolimab Plus Pembrolizumab in High-Risk Stage IIB to IV Melanoma

In an interim analysis of a phase III trial (KEYVIBE-010) reported in The Lancet Oncology, Dummer et al found that adjuvant therapy with a coformulation of the anti-TIGIT antibody vibostolimab with pe...

The ASCO Post

February 19, 2026

Stage II Melanoma: Adjuvant Pembrolizumab and Risk of New Skin Cancers

Is prior adjuvant pembrolizumab associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma? A secondary analysis of the phase III KEYN...

The ASCO Post

February 09, 2026

Guidelines Harmonize Pan-Tumor Pathologic Response to Neoadjuvant Therapy

The first unified, pan-tumor guideline framework has been released for how pathologists should evaluate and score response in the neoadjuvant setting.

The ASCO Post

February 06, 2026

World Cancer Day: Taking a Proactive Approach to the Most Commonly Diagnosed Cancer

On World Cancer Day, marked annually on February 4, it’s important to note that skin cancer is the most frequently diagnosed cancer. One in every five Americans will experience some form of skin cancer by age 70, experts say.

Baptist Health South Florida

February 06, 2026

Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans

Exposure to Agent Orange in U.S. veterans was associated with an increased odds of developing acral melanoma compared with controls with and without cutaneous melanoma, according to findings published...

The ASCO Post

February 02, 2026

Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma

A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could...

The ASCO Post

January 21, 2026

The Topical Drug Delivery Challenge

From skin penetration to stability and spreadability; here’s what to consider if you want to develop a topical therapeutic

The Medicine Maker

January 21, 2026

Bridging Structure and Biology in Eyelid Reconstruction

Optimizing the surgical approach to eyelid defect reconstruction using cryopreserved umbilical cord amniotic membrane (UC-AM)

The Ophthalmologist

January 16, 2026

Meet the Team: Eleanor Fallon, MD

Eleanor Fallon, MD, joined Roswell Park Comprehensive Cancer Center to combine her two passions: treating melanoma and non-melanoma skin cancers and research into how immunotherapy can be used to make other therapies more effective.

Roswell Park Comprehensive Cancer Center

January 09, 2026

Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma

The flipped dose for nivolumab 3 mg/kg and ipilimumab 1 mg/kg led to improved response rates and survival findings as well as lower severe immune-related toxicities compared with the standard dose of ...

The ASCO Post